Cancer & Oncology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This Phase III trial is testing new treatment combinations involving Datopotamab Deruxtecan with or without Durvalumab for people with PD-L1 positive triple-negative breast cancer, a particularly aggressive form of breast cancer. The study is recruiting patients worldwide who have locally recurrent, inoperable, or metastatic disease and aims to find options that could improve survival and quality of life compared to current chemotherapy approaches.

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

This international Phase III trial is exploring the use of Datopotamab Deruxtecan combined with Durvalumab as a neoadjuvant or adjuvant treatment for adults with triple-negative or hormone receptor-low/HER2-negative breast cancer. Nearly 2,000 participants are enrolled to see if this combination can offer effective treatment while reducing the need for chemotherapy, potentially leading to better outcomes with fewer side effects.

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

This Phase III study is testing tucatinib added to the current standard drug ado-trastuzumab emtansine (T-DM1) for adults with advanced or metastatic HER2-positive breast cancer. The goal is to see if adding tucatinib improves disease control and survival for patients whose cancer cannot be removed by surgery or has spread to other parts of the body.

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

This trial is evaluating a new combination of xaluritamig and abiraterone for men with metastatic castration-resistant prostate cancer who have not yet received chemotherapy. Recruiting worldwide, it aims to find treatments that might extend survival and offer new options before chemotherapy is needed.

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

This Phase III study is testing whether adding tarlatamab to the existing combination of durvalumab, carboplatin, and etoposide improves survival for adults newly diagnosed with extensive stage small-cell lung cancer. Patients in multiple countries are enrolling to determine if this new combination could become a better first-line treatment option.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.